QualityStocksNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files 2025 Form 10-K And Highlights Operational Progress
NRx Pharmaceuticals (NASDAQ: NRXP) announced the filing of its Form 10-K for the year ended Dec. 31, 2025, highlighting progress across its clinical-stage pipeline and HOPE Therapeutics operations, including advancing two drug candidates toward FDA approval and opening its first HOPE Therapeutics clinics focused on neuroplastic care. The company reported a reduced operating loss of $16.2 million, down from $18.5 million in 2024, alongside lower research and development and general and administrative expenses, and ended the year with approximately $7.8 million in cash, which management believes will support operations through the end of 2026. To view the full press release, visit https://ibn.fm/Qgb32…